23andMe to cut 40% of workforce, end therapeutics program
"We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships," co-founder and Chief Executive Anne Wojcicki said in a statement. "I want to thank ...
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as part of a restructuring effort to cut costs, the company said Monday.
23andMe to Cut Workforce by 40%, Discontinues Therapeutics Pipeline
The clinical trials 23andMe intends to wind-down include its two main therapeutic programs. The restructuring is expected to result in expenses of up to $12 million, and savings of more than $35 million per year,
23andMe cuts 40% of its workforce, discontinues all therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki. The company said it is evaluating strategic ...
23andMe to slash 40% of workforce as it restructures and shutters therapeutics division
Bay Area genetic testing company 23andMe announced Monday that it plans to lay off 40% of its workforce as part of a broader restructuring effort aimed at cutting costs and refocusing the company on its core business.
DNA-testing site 23andMe to lay off 40% of its workers
The struggling genetic testing company 23andMe says it will cut 40% of its workforce, or 200 jobs, as it fights for survival.
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe said on Monday that it was firing roughly 40% of its workforce, more than 200 people, as Chief ...
23andMe appoints three former CFOs as new directors—after the previous board all resigned
On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 millionDiscontinues development of therapeutics division and ...
Yahoo Finance11d
23andMe’s entire board resigned on the same day. Founder Anne Wojcicki still thinks the startup is savable
Anne Wojcicki wanted to run things—alone. It was 2009 and her startup 23andMe was riding high, fueled by a steady stream of venture money, intriguing personal accounts of genome exploration ...
CNBC on MSN13d
23andMe appoints three new board members following abrupt resignations
Andre Fernandez, Jim Frankola and Mark Jensen will join the company's CEO Anne Wojcicki on the board. 23andMe appointed three ...
Pittsburgh Post-Gazette on MSN5d
Nila Bala: The risks of sharing your DNA with online companies aren’t a future concern. They’re here now
DNA commodification is no longer a future concern; it’s a present reality. Beyond charging users for their services, some ...
CTV News6h
23andMe cuts 40 per cent of its workforce, discontinues all therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...
Honolulu Star-Advertiser1d
23andMe cuts 40% of its workforce, stops therapy programs
“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki.